Indegene Ltd Stock Price Today (NSE: INDGN)
Fundamental Score
Indegene Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Indegene Ltd share price today is ₹515.90, up +0.06% on NSE/BSE as of 17 June 2026. Indegene Ltd (INDGN) is a Mid-cap company in the Healthcare Research, Analytics & Technology sector with a market capitalisation of ₹12.66K (Cr). The 52-week high for INDGN share price is ₹602.00 and the 52-week low is ₹414.00. At a P/E ratio of 28.40x, INDGN is currently trading below its industry average P/E of 45.95x. The company has a Return on Equity (ROE) of 20.59% and a debt-to-equity ratio of 0.04.
Indegene Ltd Share Price Chart — NSE/BSE Historical Performance
Indegene Ltd share price chart: 5.29% return over the past month. 52-week high ₹602.00, 52-week low ₹414.00.
Indegene Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹510.00 | ₹520.55 | ₹510.00 | ₹518.45 | 2.24L (Cr) | |
| ₹525.50 | ₹530.00 | ₹508.55 | ₹509.75 | 1.37L (Cr) | |
| ₹523.45 | ₹535.00 | ₹508.10 | ₹521.55 | 5.82L (Cr) | |
| ₹524.20 | ₹532.00 | ₹514.35 | ₹518.90 | 1.72L (Cr) | |
| ₹521.75 | ₹525.00 | ₹514.15 | ₹517.55 | 1.12L (Cr) | |
| ₹509.05 | ₹525.65 | ₹509.05 | ₹516.60 | 1.78L (Cr) | |
| ₹509.25 | ₹514.25 | ₹507.05 | ₹508.55 | 72.29K (Cr) | |
| ₹510.15 | ₹517.85 | ₹507.15 | ₹509.25 | 72.49K (Cr) | |
| ₹504.20 | ₹519.80 | ₹504.20 | ₹513.60 | 2.41L (Cr) | |
| ₹512.30 | ₹520.00 | ₹508.00 | ₹511.40 | 68.36K (Cr) |
Indegene Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹525.50 | ₹530.00 | ₹508.55 | ₹518.45 | -1.34% | |
| ₹499.75 | ₹554.00 | ₹499.75 | ₹521.55 | +4.36% | |
| ₹456.40 | ₹508.45 | ₹442.35 | ₹499.75 | +9.50% | |
| ₹480.00 | ₹488.00 | ₹414.00 | ₹434.60 | -9.46% | |
| ₹480.45 | ₹511.75 | ₹460.50 | ₹496.30 | +3.30% | |
| ₹520.25 | ₹526.60 | ₹455.60 | ₹482.40 | -7.28% | |
| ₹532.65 | ₹544.00 | ₹513.85 | ₹520.45 | -2.29% | |
| ₹544.75 | ₹544.75 | ₹502.80 | ₹531.30 | -2.47% | |
| ₹562.70 | ₹587.30 | ₹531.00 | ₹539.40 | -4.14% | |
| ₹543.85 | ₹596.80 | ₹536.00 | ₹561.00 | +3.15% | |
| ₹562.95 | ₹593.40 | ₹539.75 | ₹542.30 | -3.67% | |
| ₹577.00 | ₹586.00 | ₹534.20 | ₹543.00 | -5.89% |
AI Research Briefing
Powered by Gemini · 2026-04-09
Overvalued mid-cap growth stock in healthcare analytics faces high execution risk; watch for a better entry point.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Indegene's stock has been under pressure, hitting an all-time low of on March 23, 2026. This decline occurred despite a more resilient broader market. The company responded to BSE inquiries regarding increased trading volume, stating no undisclosed material events were pending. Indegene Healthcare UK Limited completed a Trade and Asset Purchase Agreement with Trilogy Writing and Consulting Limited for GBP 1,90,679 on April 1, 2026. This transaction is an internal group consolidation.
CORE STORY (THE REAL GAME)
Indegene is being priced as a high-growth digital-first life sciences commercialization play, leveraging AI and analytics. The market is focused on its ability to scale its solutions and capitalize on the increasing digitization of the healthcare industry in India and globally.
- Healthcare analytics market growth in India
- Strategic acquisitions for inorganic growth
- Increased digitization of healthcare
- Significant order wins
- Strong quarterly earnings beats
- Successful integration of acquired entities
- Elevated valuation multiples
- Underperformance compared to benchmark indices
- Mid-cap liquidity risk
FII holdings increased by 1.26%, while DII holdings decreased by 0.25%.
Government initiatives like Ayushman Bharat and the National Digital Health Mission are tailwinds for the healthcare analytics market.
Indegene Healthcare UK Limited completed a Trade and Asset Purchase Agreement with Trilogy Writing and Consulting Limited for GBP 1,90,679 on April 1, 2026.
Yes, Free Cash Flow 5Y: ₹1444.04 Cr.
Monitor for consistent revenue growth and margin expansion over the next few quarters. Key is successful integration of acquisitions and capitalizing on the digital healthcare trend.
Primary Thesis Risk
Failure to sustain high growth rates will lead to valuation multiple contraction.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Indegene Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Indegene Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of INDGN across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (20.59%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (24.80%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (18.97%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 28.40 vs Industry: 45.95)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Revenue Growth (17.09%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (34.59% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (15.71% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (67.93% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.04)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (43.09x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹1444.04 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Low Promoter Commitment (0.00%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
Indegene Ltd vs Healthcare Research, Analytics & Technology Peers
Peer Comparison - Healthcare Research, Analytics & Technology
Compare Indegene Ltd with 8 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Indegene LtdIndegene Ltd...Selected✓ INDGN • 544172 | 66.8/100 | ₹515.90₹516 | ₹12660.10₹12660.10 | 28.40Average 28.4 Average | 20.59%Excellent 20.59% Excellent | 24.80%Excellent 24.80% Excellent | 0.04Excellent 0.0 Excellent | 67.93%Excellent 67.93% Excellent | 34.59%Excellent 34.59% Excellent | 0.38% |
Syngene International LtdSyngene Interna... SYNGENE • 539268 | 41.6/100 | ₹466.30₹466 | ₹25985.68₹25985.68 | 55.50Average 55.5 Average | 10.53%Average 10.53% Average | 13.52%Average 13.52% Average | 0.12Excellent 0.1 Excellent | 5.71%Good 5.71% Good | 12.60%Good 12.60% Good | 0.19% |
Suven Life Sciences LtdSuven Life Scie... SUVEN • 530239 | 6.5/100 | ₹269.43₹269 | ₹3927.58₹3927.58 | — — | -87.22%Poor -87.22% Poor | -86.96%Poor -86.96% Poor | 0.00Excellent 0.0 Excellent | -24.19%Poor -24.19% Poor | -12.00%Poor -12.00% Poor | 0.00% |
Vimta Labs LtdVimta Labs Ltd... VIMTALABS • 524394 | 65.8/100 | ₹453.10₹453 | ₹2716.50₹2716.50 | 36.39Average 36.4 Average | 19.43%Good 19.43% Good | 25.22%Excellent 25.22% Excellent | 0.02Excellent 0.0 Excellent | 58.03%Excellent 58.03% Excellent | 13.74%Good 13.74% Good | 0.16% |
Take Solutions LtdTake Solutions ... TAKE • 532890 | 19.5/100 | ₹25.53₹26 | ₹481.24₹481.24 | 120.61Average 120.6 Average | 644.12%Excellent 644.12% Excellent | 11.24%Average 11.24% Average | 0.00Excellent 0.0 Excellent | 38.14%Excellent 38.14% Excellent | — — | 0.00% |
Bilcare LtdBilcare Ltd... BI • 526853 | 6.9/100 | ₹62.20₹62 | ₹200.42₹200.42 | — — | -5.58%Poor -5.58% Poor | 1.10%Poor 1.10% Poor | 1.48Average 1.5 Average | 13.81%Good 13.81% Good | -15.48%Poor -15.48% Poor | 0.00% |
NOVELIX PHARMACEUTICALS LIMITENOVELIX PHARMAC... NOVELIX • 536565 | 40.6/100 | ₹54.00₹54 | ₹101.70₹101.70 | 104.85Average 104.8 Average | 0.64%Poor 0.64% Poor | 0.96%Poor 0.96% Poor | 0.00Excellent 0.0 Excellent | -2.33%Poor -2.33% Poor | 82.92%Excellent 82.92% Excellent | 0.00% |
Adeshwar Meditex LtdAdeshwar Medite... ADESHWAR • 543309 | 29.2/100 | ₹18.41₹18 | ₹25.54₹25.54 | 12.34Average 12.3 Average | 5.51%Poor 5.51% Poor | 8.27%Poor 8.27% Poor | 0.16Excellent 0.2 Excellent | -1.36%Poor -1.36% Poor | 8.33%Good 8.33% Good | 0.00% |
Vanta Bioscience LtdVanta Bioscienc... VANTABIO • 540729 | 7.2/100 | ₹24.45₹24 | ₹16.84₹16.84 | — — | -37.24%Poor -37.24% Poor | -11.58%Poor -11.58% Poor | 1.59Average 1.6 Average | — — | -32.27%Poor -32.27% Poor | 0.00% |
Top Healthcare Research, Analytics & Technology Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Syngene International Ltd share price25985.68 Cr
- Suven Life Sciences Ltd share price3927.58 Cr
- Vimta Labs Ltd share price2716.50 Cr
- Take Solutions Ltd share price481.24 Cr
- Bilcare Ltd share price200.42 Cr
Indegene Ltd PE Ratio History
Historical price-to-earnings ratio for INDGN — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹17.02 | ₹520.45 | 30.6x |
| FY 2024 | ₹14.09 | ₹603.70 | 42.8x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Indegene Ltd Quarterly Performance
Latest quarterly metrics for INDGN — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
17.09%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
11.34%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
34.59%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
67.93%
Compounded annual net profit growth over 5 years
Indegene Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for INDGN — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Indegene Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Indegene Ltd (INDGN) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Indegene Ltd
About INDGN (Indegene Ltd)
Indegene Ltd is a global healthcare solutions provider that is revolutionizing the way life sciences companies operate. Focusing on the intersection of healthcare, technology, and ...commercialization, Indegene empowers biopharmaceutical, emerging biotech, and medical device organizations to achieve their strategic goals. With a deep understanding of the complex healthcare landscape, Indegene offers a comprehensive suite of solutions, spanning from clinical trial optimization to digital marketing and sales force enablement. They are committed to driving innovation and efficiency across the entire product lifecycle, ultimately accelerating the delivery of life-saving therapies to patients in need. At the core of Indegene's capabilities lies a robust foundation in data analytics, artificial intelligence, and digital technologies. They leverage these tools to uncover actionable insights, optimize marketing campaigns, and personalize patient engagement strategies. Indegene helps clients to transform complex medical data into easily digestible information for patients, healthcare professionals, and payers. Through its enterprise commercial and medical solutions, Indegene partners with organizations to navigate the ever-evolving regulatory landscape and optimize their market access strategies. They also provide medical and clinical solutions that include but not limited to literature reviews, publications and more. Indegene is a catalyst for change in the healthcare industry, helping organizations embrace the power of digital transformation to improve patient outcomes. By combining deep industry expertise with cutting-edge technologies, Indegene is uniquely positioned to empower life sciences companies to thrive in the digital age. Through their omnichannel activation services, they support companies to effectively communicate with their target audiences across multiple channels, building trust and brand loyalty. Their dedication to excellence and customer-centric approach makes them a trusted partner for organizations seeking to unlock the full potential of their life-saving products.
Company Details
Key Leadership
Corporate Events
Latest News
INDGN Share Price: Frequently Asked Questions
What is the current share price of Indegene Ltd?
Indegene Ltd (INDGN) trades at ₹515.90 on NSE and BSE. Market cap ₹12.66K (Cr). Educational data only.
What is the P/E ratio of Indegene Ltd?
Indegene Ltd has a P/E of 28.40x vs industry average 45.95x.
What is the Bull Run score for Indegene Ltd?
Indegene Ltd has a Bull Run score of 66.8/100 based on 25+ financial parameters.
Does Indegene Ltd pay dividends?
Indegene Ltd has a dividend yield of 0.38%. Past dividends don't guarantee future payments.
What is the ROE of Indegene Ltd?
Indegene Ltd has ROE of 20.59%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Indegene Ltd?
Indegene Ltd has debt-to-equity of 0.04.
Is Indegene Ltd a good investment?
Bull Run gives Indegene Ltd a score of 66.8/100. This is not investment advice — consult a SEBI-registered advisor.